Drug intelligence / Profile preview

PMPN-DP

Development stage: Unknown
Lead developer: Qurgen
Modality: Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

PMPN-DP is an investigational transcription factor protein drug (TFPD) being developed by Qurgen for the treatment of diabetes. The therapeutic is designed using Qurgen's proprietary protein delivery platform, which enables the intracellular delivery of transcription factors to modulate gene expression. PMPN-DP aims to restore insulin production by promoting the regeneration or transdifferentiation of pancreatic cells into functional, insulin-secreting beta cells. The drug is currently in Phase 1 clinical development.

Beyond the preview

Go deeper on PMPN-DP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PMPN-DP.

Explore the full profile